(Q34982478)

English

Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

5 August 2017

Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical). (English)

1 reference

Europe PubMed Central

5 August 2017

phase II clinical trial

0 references

0 references

0 references

Stephan Rössner

4

object named as

Stephan Rossner

1 reference

Europe PubMed Central

5 August 2017

author name string

Peter Kopelman

1

1 reference

Europe PubMed Central

5 August 2017

Gerrit de H Groot

2

1 reference

Europe PubMed Central

5 August 2017

Aila Rissanen

3

1 reference

Europe PubMed Central

5 August 2017

Soren Toubro

5

1 reference

Europe PubMed Central

5 August 2017

Richard Palmer

6

1 reference

Europe PubMed Central

5 August 2017

Rob Hallam

7

1 reference

Europe PubMed Central

5 August 2017

Andrew Bryson

8

1 reference

Europe PubMed Central

5 August 2017

Roger I Hickling

9

1 reference

Europe PubMed Central

5 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

21 May 2009

1 reference

Europe PubMed Central

5 August 2017

1 reference

Europe PubMed Central

5 August 2017

18

1 reference

Europe PubMed Central

5 August 2017

1

1 reference

Europe PubMed Central

5 August 2017

108-115

1 reference

Europe PubMed Central

5 August 2017

Weight gain as a risk factor for clinical diabetes mellitus in women

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.155

21 January 2018

Effect of weight loss and nutritional intervention on arterial stiffness in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.155

21 January 2018

Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.155

21 January 2018

Management of obesity in patients with Type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.155

21 January 2018

Metabolic consequences of weight loss on glucose metabolism and insulin action in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.155

21 January 2018

Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.155

21 January 2018

A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.155

21 January 2018

The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.155

21 January 2018

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.155

21 January 2018

Drug Insight: appetite suppressants

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.155

21 January 2018

Pharmacological therapies for obesity

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.155

21 January 2018

Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.155

21 January 2018

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.155

21 January 2018

A randomized trial of lifestyle intervention in primary healthcare for the modification of cardiovascular risk factors The Björknäs study

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.155

31 March 2020

Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.155

31 March 2020

Identifiers

10.1038/OBY.2009.155

1 reference

Europe PubMed Central

5 August 2017

1 reference

Europe PubMed Central

5 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34982478&oldid=1981054249"